Skip to main content

Viridian Therapeutics, Inc. (VRDN) Stock

Viridian Therapeutics, Inc. Stock Details, Movements and Public Alerts

Stock Details

Viridian Therapeutics, Inc. (VRDN), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NCM.Currently, the stock is trading at $28.76. Over the past 52 weeks, it has ranged between $9.90 and $34.29. This places the current price at 83.9% of its 52-week high and 190.5% above its 52-week low. Recent trading volume was recorded at 576,121. The 14-day Relative Strength Index (RSI) stands at 43.62, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $30.57 by 5.92%. Similarly, it is above its 200-day moving average of $23.64 by 21.66%. The MACD histogram is 0.05, indicating bullish momentum (MACD Line: -0.43, Signal Line: -0.48). There is currently 1 active alert set for VRDN by users.

52-Week Range

$34.29 - $9.90

-16.13% from high · +190.51% from low

Avg Daily Volume

1,260,664

20-day average

100-day avg: 1,581,394

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-13.87

Price to Book

4.90

EV/EBITDA

-6.10

EPS (TTM)

-$3.32

Price to Sales

40.98

Beta

1.01

Similar volatility to market

Q:How is VRDN valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is VRDN's risk profile compared to the market?
With a beta of 1.01, Viridian Therapeutics, Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 4.90 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-95643.18%

EBITDA

$-362,935,008

Return on Equity

-49.16%

Return on Assets

-27.67%

Revenue Growth (YoY)

83.30%

Q:How profitable and efficient is VRDN's business model?
0 The operating margin of -95643.18% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -49.16% and ROA at -27.67%, the company achieves moderate returns on invested capital.
Q:What are VRDN's recent growth trends?
Viridian Therapeutics, Inc.'s revenue grew by 83.30% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$2.9B

Revenue (TTM)

$70.85M

Revenue/Share (TTM)

$0.84

Shares Outstanding

102.21M

Book Value/Share

$5.80

Asset Type

EQUITY

Q:What is VRDN's market capitalization and position?
Viridian Therapeutics, Inc. has a market capitalization of $2.9B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 102.21M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does VRDN's price compare to its book value?
Viridian Therapeutics, Inc.'s book value per share is $5.80, while the current stock price is $28.76, resulting in a price-to-book (P/B) ratio of 4.96. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$41.76

45.22% upside potential

Analyst Recommendations

Strong Buy

3

Buy

13

Hold

1

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for VRDN?
17 analysts cover VRDN with 94% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $41.76 implies 45.2% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on VRDN?
Current analyst recommendations:3 Strong Buy, 13 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 13, 2026, 02:11 AM

Technical Indicators

RSI (14-day)

43.62

Neutral

50-Day Moving Average

$30.57

-5.92% below MA-50

200-Day Moving Average

$23.64

21.66% above MA-200

MACD Line

-0.43

MACD Signal

-0.48

MACD Histogram

0.05

Bullish

Q:What does VRDN's RSI value tell investors?
The RSI (Relative Strength Index) for VRDN is currently 43.62, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret VRDN's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.43 above the signal line at -0.48, with histogram at 0.05. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($30.57) is above the 200-day MA ($23.64), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Mar 13, 2026, 01:37 PM

Active Alerts

Alert Condition
RSI Threshold Cross
Threshold
30
Created
Feb 5, 2026, 05:02 PM

Stay Ahead of the Market with Viridian Therapeutics, Inc. Alerts

Set up price alerts for Viridian Therapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.